N-Power maintains robust security, privacy, and quality programs which adhere to globally recognized standards ensuring confidentiality, integrity, and availability of sensitive data and enforcement of quality standards in everything we do.
The First Always-On Clinical Research System in Community Oncology
Where research is part of every oncologist’s practice and every patient’s care.
Uniquely Accelerating & De-Risking Clinical Drug Development.
Product Offerings
Prospective External Controls
Robust comparator groups prospectively generated with data collection precisely mirroring the targeted trial for comparison - including comprehensive I/E criteria, NGS, prognostic covariates, standardized imaging intervals, and timing and format of biosample collection.
Multiple applications in early clinical development, including replacing or augmenting control arms of randomized phase II, enabling single arm studies, informing phase III designs, de-risking and accelerating development decision-making.
Community Trial Accelerator
Systematic, anticipatory data collection empowers physicians to discuss trial participation with their patients at the right time.
Comprehensive pre-screening across the entire population to surface every eligible participant, arming Clinical Operations teams with the data to ensure operational success.
Signal-based site activation enables sponsors and sites to deploy resources only when there are patients to enroll.
Drug development is too slow and fails too often.
Pharma has the trials but needs patients and doctors to run them.
Community Oncology has the patients & doctors but can't incorporate the trials.
- 85% of trials delayed
- 50% of phase III trials fail due to underpowered phase II or inadequate controls
- Only 5% of patients participate in trials
- 10+ Years to bring one oncology drug to market
- 80% of cancer patients are treated in the community
- 87% of doctors say research is important for patient care
- Just 1 in 8 Community Oncologists actively enroll patients
The burden of routine care has left no room for research in community oncology... until N-Power.
A radical new approach where Routine Care is Research.
N-Power delivers a novel single workflow that makes routine care and research one and the same, unlocking speed and certainty in drug development.
- Every patient participates in research ( 12,000+ Kaleido Registry patients to date, 95% consent rate )
- Research embedded into routine care workflows that physicians already use
- Physicians save 5-10 hours/ week
- Practice-wide physician engagement in research, backed by strong net promoter score
- N-Power team members and AI-enabled infrastructure at the sites to support trials locally
A consented, prospective data collection program for every patient, tailored to trials and prospective external controls from our Pharma partners.
Powered by Technology. Driven By People.
Human-in-the-loop platform powered by AI
With automation and expert human oversight to reduce clinician administrative burden of chart review, note preparation, and research navigation.
Embedded Virtual & Remote Staff
Supports all routine care patients, not just those in research studies.
Point-of-Care Technology Solution
Secure and compliant platform that operates seamlessly with any EHR, without disrupting physician workflow.
The Research Network
N-Power partners with US community oncology practices to build a hyper-local, always-on research network, bringing innovative clinical trials to where patients receive care.
- 1,000+ Oncologists
- Linkage to all major NGS labs
- 25+ Sites by end of 2025
- 100,000+ cancer cases a year
Our Commitment to Security, Privacy, and Quality.